Journal of Clinical Oncology

The Journal of Clinical Oncology (JCO) is a medical journal published 3 times a month (36 issues a year) by the American Society of Clinical Oncology (ASCO), with a 2010 impact factor of 18.970. JCO now accounts for nearly one in 10 of all oncology journal citations. This journal s focus is work that relates to the care of patients with cancer, e.g., clinical oncology. This journal publishes in varying formats. Original research reports are both a communication tool and reports for original research. Review articles can describe work that builds on previous original research, summarize the current state clinical oncology, or can be a point of critical analysis. Opinion is voiced in editorial formats, which include commentary and discuss controversies. There is also a format for perspectives from a person of public notoriety. Special articles are another form of communication besides original research reports, which promulgate guidelines, summaries of consensus, and other scholarly communications. Fundamental research is covered in the "Biology of Neoplasia" section.

Publisher
American Society of Clinical Oncology
Impact factor
18.372 (2011)

Some content from Wikipedia, licensed under CC BY-SA

Oncology & Cancer

Study reveals lower predictive ability for renal cancer models

(HealthDay)—Prospective validation of existing renal cell carcinoma (RCC) prediction models demonstrates a decrease in their predictive ability, according to a study published online June 19 in the Journal of Clinical Oncology.

Oncology & Cancer

Underenrollment in clinical trials: Patients not the problem

The increasing sophistication of cancer treatments threatens to outpace the ability of health care providers to enroll patients in clinical trials to test those therapies. That's a key finding by researchers in UT Southwestern's ...

Oncology & Cancer

Immunotherapy drug shows potential to cure advanced lung cancer

In a new study including Yale Cancer Center and Smilow Cancer Hospital researchers, the cancer immunotherapy drug pembrolizumab (Keytruda), increased survival for patients with advanced non-small cell lung cancer (NSCLC), ...

Oncology & Cancer

Prognostic disclosure improves life expectancy estimates

(HealthDay)—Prognostic disclosure is associated with more realistic patient expectations of life expectancy (LE) in advanced cancer, according to a study published online Oct. 5 in the Journal of Clinical Oncology.

page 1 from 50